nodes	percent_of_prediction	percent_of_DWPC	metapath
Haloperidol—KCNH2—purkinje fiber—dilated cardiomyopathy	0.079	0.258	CbGeAlD
Haloperidol—HTR2B—cardial valve—dilated cardiomyopathy	0.051	0.167	CbGeAlD
Haloperidol—KCNH2—endocardium—dilated cardiomyopathy	0.0407	0.133	CbGeAlD
Haloperidol—CYP2C9—cardial valve—dilated cardiomyopathy	0.0331	0.108	CbGeAlD
Haloperidol—ABCB1—Lisinopril—dilated cardiomyopathy	0.0178	0.532	CbGbCtD
Haloperidol—ABCB1—Spironolactone—dilated cardiomyopathy	0.0157	0.468	CbGbCtD
Haloperidol—Menstruation irregular—Spironolactone—dilated cardiomyopathy	0.0152	0.0428	CcSEcCtD
Haloperidol—HTR2A—pulmonary artery—dilated cardiomyopathy	0.011	0.0361	CbGeAlD
Haloperidol—HTR2A—sympathetic nervous system—dilated cardiomyopathy	0.0107	0.0351	CbGeAlD
Haloperidol—Breast pain—Spironolactone—dilated cardiomyopathy	0.00963	0.0271	CcSEcCtD
Haloperidol—Amenorrhoea—Spironolactone—dilated cardiomyopathy	0.00957	0.027	CcSEcCtD
Haloperidol—DRD4—heart—dilated cardiomyopathy	0.00767	0.0251	CbGeAlD
Haloperidol—Gynaecomastia—Spironolactone—dilated cardiomyopathy	0.00752	0.0212	CcSEcCtD
Haloperidol—CBR1—myocardium—dilated cardiomyopathy	0.00684	0.0224	CbGeAlD
Haloperidol—Lethargy—Spironolactone—dilated cardiomyopathy	0.00623	0.0175	CcSEcCtD
Haloperidol—Cholestasis—Furosemide—dilated cardiomyopathy	0.00602	0.017	CcSEcCtD
Haloperidol—H1F0—cardiac ventricle—dilated cardiomyopathy	0.00596	0.0195	CbGeAlD
Haloperidol—Inappropriate antidiuretic hormone secretion—Lisinopril—dilated cardiomyopathy	0.0059	0.0166	CcSEcCtD
Haloperidol—H1F0—myocardium—dilated cardiomyopathy	0.0056	0.0183	CbGeAlD
Haloperidol—Laryngeal oedema—Lisinopril—dilated cardiomyopathy	0.00534	0.0151	CcSEcCtD
Haloperidol—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.00486	0.0137	CcSEcCtD
Haloperidol—CBR1—heart—dilated cardiomyopathy	0.00477	0.0156	CbGeAlD
Haloperidol—Drowsiness—Spironolactone—dilated cardiomyopathy	0.0047	0.0132	CcSEcCtD
Haloperidol—Ventricular fibrillation—Lisinopril—dilated cardiomyopathy	0.00448	0.0126	CcSEcCtD
Haloperidol—Agranulocytosis—Spironolactone—dilated cardiomyopathy	0.00439	0.0124	CcSEcCtD
Haloperidol—SIGMAR1—cardiac ventricle—dilated cardiomyopathy	0.0043	0.0141	CbGeAlD
Haloperidol—Endocrine disorder—Lisinopril—dilated cardiomyopathy	0.00414	0.0117	CcSEcCtD
Haloperidol—CBR1—cardiac atrium—dilated cardiomyopathy	0.00408	0.0134	CbGeAlD
Haloperidol—SIGMAR1—myocardium—dilated cardiomyopathy	0.00405	0.0132	CbGeAlD
Haloperidol—Breast pain—Lisinopril—dilated cardiomyopathy	0.00393	0.0111	CcSEcCtD
Haloperidol—H1F0—heart—dilated cardiomyopathy	0.00391	0.0128	CbGeAlD
Haloperidol—Photosensitivity—Furosemide—dilated cardiomyopathy	0.00378	0.0107	CcSEcCtD
Haloperidol—Alopecia—Spironolactone—dilated cardiomyopathy	0.00373	0.0105	CcSEcCtD
Haloperidol—Leukocytosis—Lisinopril—dilated cardiomyopathy	0.00365	0.0103	CcSEcCtD
Haloperidol—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00353	0.00995	CcSEcCtD
Haloperidol—Dermatitis exfoliative—Furosemide—dilated cardiomyopathy	0.00352	0.00991	CcSEcCtD
Haloperidol—Ventricular tachycardia—Lisinopril—dilated cardiomyopathy	0.00343	0.00967	CcSEcCtD
Haloperidol—KCNH2—cardiac ventricle—dilated cardiomyopathy	0.00342	0.0112	CbGeAlD
Haloperidol—Lethargy—Furosemide—dilated cardiomyopathy	0.00339	0.00955	CcSEcCtD
Haloperidol—H1F0—cardiac atrium—dilated cardiomyopathy	0.00335	0.0109	CbGeAlD
Haloperidol—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.00333	0.00939	CcSEcCtD
Haloperidol—Salivary hypersecretion—Lisinopril—dilated cardiomyopathy	0.00333	0.00939	CcSEcCtD
Haloperidol—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00329	0.00927	CcSEcCtD
Haloperidol—KCNH2—myocardium—dilated cardiomyopathy	0.00322	0.0105	CbGeAlD
Haloperidol—Urinary retention—Furosemide—dilated cardiomyopathy	0.00316	0.00889	CcSEcCtD
Haloperidol—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.00303	0.00854	CcSEcCtD
Haloperidol—Confusional state—Spironolactone—dilated cardiomyopathy	0.00302	0.00852	CcSEcCtD
Haloperidol—Hypertonia—Lisinopril—dilated cardiomyopathy	0.00301	0.00847	CcSEcCtD
Haloperidol—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.003	0.00845	CcSEcCtD
Haloperidol—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00294	0.00827	CcSEcCtD
Haloperidol—CYP1A1—cardiac ventricle—dilated cardiomyopathy	0.00289	0.00946	CbGeAlD
Haloperidol—Hepatic function abnormal—Lisinopril—dilated cardiomyopathy	0.00285	0.00803	CcSEcCtD
Haloperidol—Photosensitivity—Lisinopril—dilated cardiomyopathy	0.00284	0.00799	CcSEcCtD
Haloperidol—SIGMAR1—heart—dilated cardiomyopathy	0.00283	0.00924	CbGeAlD
Haloperidol—HTR2B—heart—dilated cardiomyopathy	0.00282	0.00922	CbGeAlD
Haloperidol—Libido decreased—Lisinopril—dilated cardiomyopathy	0.00269	0.00757	CcSEcCtD
Haloperidol—Somnolence—Spironolactone—dilated cardiomyopathy	0.00267	0.00751	CcSEcCtD
Haloperidol—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.00262	0.00738	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00259	0.0073	CcSEcCtD
Haloperidol—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.00259	0.00729	CcSEcCtD
Haloperidol—Drowsiness—Furosemide—dilated cardiomyopathy	0.00256	0.00721	CcSEcCtD
Haloperidol—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.00255	0.00719	CcSEcCtD
Haloperidol—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.0025	0.00705	CcSEcCtD
Haloperidol—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00247	0.00696	CcSEcCtD
Haloperidol—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.00247	0.00696	CcSEcCtD
Haloperidol—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00242	0.00682	CcSEcCtD
Haloperidol—SIGMAR1—cardiac atrium—dilated cardiomyopathy	0.00242	0.0079	CbGeAlD
Haloperidol—Face oedema—Lisinopril—dilated cardiomyopathy	0.0024	0.00678	CcSEcCtD
Haloperidol—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.00239	0.00673	CcSEcCtD
Haloperidol—Urticaria—Spironolactone—dilated cardiomyopathy	0.00238	0.00671	CcSEcCtD
Haloperidol—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00237	0.00668	CcSEcCtD
Haloperidol—Cardiac arrest—Lisinopril—dilated cardiomyopathy	0.00237	0.00667	CcSEcCtD
Haloperidol—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.00227	0.00641	CcSEcCtD
Haloperidol—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00227	0.00639	CcSEcCtD
Haloperidol—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00225	0.00634	CcSEcCtD
Haloperidol—Breast disorder—Lisinopril—dilated cardiomyopathy	0.00225	0.00634	CcSEcCtD
Haloperidol—KCNH2—heart—dilated cardiomyopathy	0.00225	0.00736	CbGeAlD
Haloperidol—Visual impairment—Furosemide—dilated cardiomyopathy	0.00221	0.00624	CcSEcCtD
Haloperidol—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00221	0.00623	CcSEcCtD
Haloperidol—Eye disorder—Furosemide—dilated cardiomyopathy	0.00215	0.00605	CcSEcCtD
Haloperidol—Pruritus—Spironolactone—dilated cardiomyopathy	0.00212	0.00598	CcSEcCtD
Haloperidol—Bronchospasm—Lisinopril—dilated cardiomyopathy	0.00212	0.00597	CcSEcCtD
Haloperidol—Sweating increased—Lisinopril—dilated cardiomyopathy	0.0021	0.00591	CcSEcCtD
Haloperidol—Angiopathy—Furosemide—dilated cardiomyopathy	0.00208	0.00587	CcSEcCtD
Haloperidol—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00207	0.00584	CcSEcCtD
Haloperidol—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00205	0.00578	CcSEcCtD
Haloperidol—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.00204	0.00576	CcSEcCtD
Haloperidol—Neutropenia—Lisinopril—dilated cardiomyopathy	0.00201	0.00567	CcSEcCtD
Haloperidol—Malnutrition—Furosemide—dilated cardiomyopathy	0.002	0.00563	CcSEcCtD
Haloperidol—Dizziness—Spironolactone—dilated cardiomyopathy	0.00198	0.00559	CcSEcCtD
Haloperidol—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.00198	0.00559	CcSEcCtD
Haloperidol—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.00196	0.00554	CcSEcCtD
Haloperidol—Weight increased—Lisinopril—dilated cardiomyopathy	0.00196	0.00552	CcSEcCtD
Haloperidol—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00195	0.00549	CcSEcCtD
Haloperidol—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.00194	0.00547	CcSEcCtD
Haloperidol—KCNH2—cardiac atrium—dilated cardiomyopathy	0.00192	0.00629	CbGeAlD
Haloperidol—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00192	0.00542	CcSEcCtD
Haloperidol—Depression—Lisinopril—dilated cardiomyopathy	0.00191	0.00539	CcSEcCtD
Haloperidol—Vomiting—Spironolactone—dilated cardiomyopathy	0.00191	0.00537	CcSEcCtD
Haloperidol—CYP1A1—heart—dilated cardiomyopathy	0.0019	0.00621	CbGeAlD
Haloperidol—Rash—Spironolactone—dilated cardiomyopathy	0.00189	0.00533	CcSEcCtD
Haloperidol—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00189	0.00532	CcSEcCtD
Haloperidol—Vision blurred—Furosemide—dilated cardiomyopathy	0.00188	0.00531	CcSEcCtD
Haloperidol—Headache—Spironolactone—dilated cardiomyopathy	0.00188	0.00529	CcSEcCtD
Haloperidol—Jaundice—Lisinopril—dilated cardiomyopathy	0.00187	0.00527	CcSEcCtD
Haloperidol—Anaemia—Furosemide—dilated cardiomyopathy	0.00185	0.00521	CcSEcCtD
Haloperidol—Agitation—Furosemide—dilated cardiomyopathy	0.00184	0.00518	CcSEcCtD
Haloperidol—CYP2C9—heart—dilated cardiomyopathy	0.00183	0.00598	CbGeAlD
Haloperidol—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00182	0.00512	CcSEcCtD
Haloperidol—Vertigo—Furosemide—dilated cardiomyopathy	0.0018	0.00506	CcSEcCtD
Haloperidol—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.00179	0.00505	CcSEcCtD
Haloperidol—Leukopenia—Furosemide—dilated cardiomyopathy	0.00179	0.00504	CcSEcCtD
Haloperidol—Nausea—Spironolactone—dilated cardiomyopathy	0.00178	0.00502	CcSEcCtD
Haloperidol—Hepatitis—Lisinopril—dilated cardiomyopathy	0.00172	0.00486	CcSEcCtD
Haloperidol—Hallucination—Lisinopril—dilated cardiomyopathy	0.00171	0.00483	CcSEcCtD
Haloperidol—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.0017	0.00479	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00169	0.00476	CcSEcCtD
Haloperidol—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00169	0.00476	CcSEcCtD
Haloperidol—Dry mouth—Furosemide—dilated cardiomyopathy	0.00166	0.00469	CcSEcCtD
Haloperidol—Confusional state—Furosemide—dilated cardiomyopathy	0.00165	0.00464	CcSEcCtD
Haloperidol—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00163	0.0046	CcSEcCtD
Haloperidol—Fluspirilene—ADRB1—dilated cardiomyopathy	0.00163	1	CrCbGaD
Haloperidol—CYP1A1—cardiac atrium—dilated cardiomyopathy	0.00162	0.00531	CbGeAlD
Haloperidol—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.0016	0.00451	CcSEcCtD
Haloperidol—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.0016	0.0045	CcSEcCtD
Haloperidol—Skin disorder—Furosemide—dilated cardiomyopathy	0.00158	0.00447	CcSEcCtD
Haloperidol—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00158	0.00444	CcSEcCtD
Haloperidol—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00156	0.00441	CcSEcCtD
Haloperidol—Anorexia—Furosemide—dilated cardiomyopathy	0.00156	0.00438	CcSEcCtD
Haloperidol—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00155	0.00438	CcSEcCtD
Haloperidol—Hypotension—Furosemide—dilated cardiomyopathy	0.00152	0.0043	CcSEcCtD
Haloperidol—Alopecia—Lisinopril—dilated cardiomyopathy	0.00152	0.00429	CcSEcCtD
Haloperidol—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00151	0.00425	CcSEcCtD
Haloperidol—HTR2A—heart—dilated cardiomyopathy	0.00151	0.00492	CbGeAlD
Haloperidol—Malnutrition—Lisinopril—dilated cardiomyopathy	0.0015	0.00423	CcSEcCtD
Haloperidol—Somnolence—Furosemide—dilated cardiomyopathy	0.00145	0.00409	CcSEcCtD
Haloperidol—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00144	0.00406	CcSEcCtD
Haloperidol—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00142	0.004	CcSEcCtD
Haloperidol—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00141	0.00398	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00141	0.00397	CcSEcCtD
Haloperidol—Tremor—Lisinopril—dilated cardiomyopathy	0.00141	0.00396	CcSEcCtD
Haloperidol—Constipation—Furosemide—dilated cardiomyopathy	0.0014	0.00393	CcSEcCtD
Haloperidol—Anaemia—Lisinopril—dilated cardiomyopathy	0.00139	0.00391	CcSEcCtD
Haloperidol—Vertigo—Lisinopril—dilated cardiomyopathy	0.00135	0.0038	CcSEcCtD
Haloperidol—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00134	0.00379	CcSEcCtD
Haloperidol—Leukopenia—Lisinopril—dilated cardiomyopathy	0.00134	0.00378	CcSEcCtD
Haloperidol—Urticaria—Furosemide—dilated cardiomyopathy	0.0013	0.00365	CcSEcCtD
Haloperidol—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00129	0.00363	CcSEcCtD
Haloperidol—Anxiety—Lisinopril—dilated cardiomyopathy	0.00127	0.00359	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00127	0.00357	CcSEcCtD
Haloperidol—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00125	0.00352	CcSEcCtD
Haloperidol—Confusional state—Lisinopril—dilated cardiomyopathy	0.00123	0.00348	CcSEcCtD
Haloperidol—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00122	0.00345	CcSEcCtD
Haloperidol—Oedema—Lisinopril—dilated cardiomyopathy	0.00122	0.00345	CcSEcCtD
Haloperidol—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.0012	0.00339	CcSEcCtD
Haloperidol—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.0012	0.00338	CcSEcCtD
Haloperidol—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00119	0.00337	CcSEcCtD
Haloperidol—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00119	0.00335	CcSEcCtD
Haloperidol—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00118	0.00333	CcSEcCtD
Haloperidol—Anorexia—Lisinopril—dilated cardiomyopathy	0.00117	0.00329	CcSEcCtD
Haloperidol—Pruritus—Furosemide—dilated cardiomyopathy	0.00115	0.00325	CcSEcCtD
Haloperidol—Hypotension—Lisinopril—dilated cardiomyopathy	0.00114	0.00322	CcSEcCtD
Haloperidol—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00112	0.00315	CcSEcCtD
Haloperidol—Insomnia—Lisinopril—dilated cardiomyopathy	0.00111	0.00312	CcSEcCtD
Haloperidol—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00109	0.00308	CcSEcCtD
Haloperidol—Somnolence—Lisinopril—dilated cardiomyopathy	0.00109	0.00307	CcSEcCtD
Haloperidol—Dizziness—Furosemide—dilated cardiomyopathy	0.00108	0.00304	CcSEcCtD
Haloperidol—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00108	0.00304	CcSEcCtD
Haloperidol—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00106	0.003	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00106	0.00298	CcSEcCtD
Haloperidol—Constipation—Lisinopril—dilated cardiomyopathy	0.00105	0.00295	CcSEcCtD
Haloperidol—Vomiting—Furosemide—dilated cardiomyopathy	0.00104	0.00292	CcSEcCtD
Haloperidol—Rash—Furosemide—dilated cardiomyopathy	0.00103	0.0029	CcSEcCtD
Haloperidol—Dermatitis—Furosemide—dilated cardiomyopathy	0.00103	0.0029	CcSEcCtD
Haloperidol—Headache—Furosemide—dilated cardiomyopathy	0.00102	0.00288	CcSEcCtD
Haloperidol—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00101	0.00284	CcSEcCtD
Haloperidol—ABCB1—heart—dilated cardiomyopathy	0.000986	0.00323	CbGeAlD
Haloperidol—Urticaria—Lisinopril—dilated cardiomyopathy	0.000972	0.00274	CcSEcCtD
Haloperidol—Nausea—Furosemide—dilated cardiomyopathy	0.000969	0.00273	CcSEcCtD
Haloperidol—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000968	0.00273	CcSEcCtD
Haloperidol—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000902	0.00254	CcSEcCtD
Haloperidol—Pruritus—Lisinopril—dilated cardiomyopathy	0.000866	0.00244	CcSEcCtD
Haloperidol—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000838	0.00236	CcSEcCtD
Haloperidol—Dizziness—Lisinopril—dilated cardiomyopathy	0.000809	0.00228	CcSEcCtD
Haloperidol—Vomiting—Lisinopril—dilated cardiomyopathy	0.000778	0.00219	CcSEcCtD
Haloperidol—Rash—Lisinopril—dilated cardiomyopathy	0.000772	0.00217	CcSEcCtD
Haloperidol—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000771	0.00217	CcSEcCtD
Haloperidol—Headache—Lisinopril—dilated cardiomyopathy	0.000767	0.00216	CcSEcCtD
Haloperidol—Nausea—Lisinopril—dilated cardiomyopathy	0.000727	0.00205	CcSEcCtD
Haloperidol—DRD3—Signaling by GPCR—AGTR1—dilated cardiomyopathy	9.18e-05	0.000302	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—CXCL2—dilated cardiomyopathy	9.14e-05	0.0003	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—AGTR2—dilated cardiomyopathy	9.14e-05	0.0003	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—PSEN2—dilated cardiomyopathy	9.09e-05	0.000299	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	9.08e-05	0.000298	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	9.06e-05	0.000298	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—AGTR2—dilated cardiomyopathy	8.99e-05	0.000295	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—CXCL2—dilated cardiomyopathy	8.99e-05	0.000295	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	8.97e-05	0.000295	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	8.97e-05	0.000295	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—PSEN2—dilated cardiomyopathy	8.94e-05	0.000294	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	8.91e-05	0.000293	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	8.89e-05	0.000292	CbGpPWpGaD
Haloperidol—GRIN2B—Developmental Biology—EGFR—dilated cardiomyopathy	8.88e-05	0.000292	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	8.83e-05	0.00029	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—ADRB2—dilated cardiomyopathy	8.71e-05	0.000286	CbGpPWpGaD
Haloperidol—HTR1D—GPCR downstream signaling—RAC1—dilated cardiomyopathy	8.7e-05	0.000286	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	8.55e-05	0.000281	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—PSEN2—dilated cardiomyopathy	8.54e-05	0.000281	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—ANKRD1—dilated cardiomyopathy	8.52e-05	0.00028	CbGpPWpGaD
Haloperidol—HTR1B—GPCR downstream signaling—RAC1—dilated cardiomyopathy	8.52e-05	0.00028	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—CXCR3—dilated cardiomyopathy	8.49e-05	0.000279	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—SDHA—dilated cardiomyopathy	8.48e-05	0.000279	CbGpPWpGaD
Haloperidol—GRIN2B—Developmental Biology—TNF—dilated cardiomyopathy	8.46e-05	0.000278	CbGpPWpGaD
Haloperidol—DRD4—GPCR downstream signaling—RAC1—dilated cardiomyopathy	8.38e-05	0.000275	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—CXCR3—dilated cardiomyopathy	8.36e-05	0.000275	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	8.34e-05	0.000274	CbGpPWpGaD
Haloperidol—HTR1D—GPCR downstream signaling—AGT—dilated cardiomyopathy	8.31e-05	0.000273	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—AGTR2—dilated cardiomyopathy	8.24e-05	0.000271	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—CXCL2—dilated cardiomyopathy	8.24e-05	0.000271	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—ADRB1—dilated cardiomyopathy	8.23e-05	0.00027	CbGpPWpGaD
Haloperidol—HTR1B—GPCR downstream signaling—AGT—dilated cardiomyopathy	8.14e-05	0.000267	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—ADRB1—dilated cardiomyopathy	8.09e-05	0.000266	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	8.08e-05	0.000265	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CXCL2—dilated cardiomyopathy	8.07e-05	0.000265	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—AGTR2—dilated cardiomyopathy	8.07e-05	0.000265	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	8.07e-05	0.000265	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—PSEN2—dilated cardiomyopathy	8.05e-05	0.000265	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—TAZ—dilated cardiomyopathy	8.01e-05	0.000263	CbGpPWpGaD
Haloperidol—DRD4—GPCR downstream signaling—AGT—dilated cardiomyopathy	8.01e-05	0.000263	CbGpPWpGaD
Haloperidol—HTR2B—GPCR downstream signaling—RAC1—dilated cardiomyopathy	8e-05	0.000263	CbGpPWpGaD
Haloperidol—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	8e-05	0.000263	CbGpPWpGaD
Haloperidol—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	7.98e-05	0.000262	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—PSEN2—dilated cardiomyopathy	7.94e-05	0.000261	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CXCL2—dilated cardiomyopathy	7.94e-05	0.000261	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—AGTR2—dilated cardiomyopathy	7.94e-05	0.000261	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—RAC1—dilated cardiomyopathy	7.9e-05	0.00026	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	7.74e-05	0.000254	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—RAC1—dilated cardiomyopathy	7.74e-05	0.000254	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—CXCR3—dilated cardiomyopathy	7.66e-05	0.000252	CbGpPWpGaD
Haloperidol—HTR2B—GPCR downstream signaling—AGT—dilated cardiomyopathy	7.65e-05	0.000251	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—RAC1—dilated cardiomyopathy	7.61e-05	0.00025	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	7.61e-05	0.00025	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	7.6e-05	0.00025	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CXCL2—dilated cardiomyopathy	7.58e-05	0.000249	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—AGTR2—dilated cardiomyopathy	7.58e-05	0.000249	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—AGT—dilated cardiomyopathy	7.55e-05	0.000248	CbGpPWpGaD
Haloperidol—DRD1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	7.55e-05	0.000248	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CXCR3—dilated cardiomyopathy	7.5e-05	0.000246	CbGpPWpGaD
Haloperidol—DRD3—GPCR downstream signaling—RAC1—dilated cardiomyopathy	7.45e-05	0.000245	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—ADRB1—dilated cardiomyopathy	7.42e-05	0.000244	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—AGT—dilated cardiomyopathy	7.39e-05	0.000243	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CXCR3—dilated cardiomyopathy	7.38e-05	0.000243	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	7.34e-05	0.000241	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—AGT—dilated cardiomyopathy	7.27e-05	0.000239	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—RAC1—dilated cardiomyopathy	7.27e-05	0.000239	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—ADRB1—dilated cardiomyopathy	7.27e-05	0.000239	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—SDHA—dilated cardiomyopathy	7.25e-05	0.000238	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	7.22e-05	0.000237	CbGpPWpGaD
Haloperidol—DRD1—GPCR downstream signaling—AGT—dilated cardiomyopathy	7.21e-05	0.000237	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	7.21e-05	0.000237	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—ADRB1—dilated cardiomyopathy	7.15e-05	0.000235	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—AGTR2—dilated cardiomyopathy	7.15e-05	0.000235	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CXCL2—dilated cardiomyopathy	7.15e-05	0.000235	CbGpPWpGaD
Haloperidol—DRD3—GPCR downstream signaling—AGT—dilated cardiomyopathy	7.11e-05	0.000234	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CXCL2—dilated cardiomyopathy	7.05e-05	0.000232	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—AGTR2—dilated cardiomyopathy	7.05e-05	0.000232	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CXCR3—dilated cardiomyopathy	7.05e-05	0.000232	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—AGTR1—dilated cardiomyopathy	7.03e-05	0.000231	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—AGT—dilated cardiomyopathy	6.94e-05	0.000228	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	6.93e-05	0.000228	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—AGTR1—dilated cardiomyopathy	6.91e-05	0.000227	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	6.9e-05	0.000227	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—RAC1—dilated cardiomyopathy	6.85e-05	0.000225	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—ADRB1—dilated cardiomyopathy	6.83e-05	0.000224	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—RAC1—dilated cardiomyopathy	6.76e-05	0.000222	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	6.75e-05	0.000222	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—ADRB2—dilated cardiomyopathy	6.67e-05	0.000219	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CXCR3—dilated cardiomyopathy	6.65e-05	0.000218	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	6.58e-05	0.000216	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—ADRB2—dilated cardiomyopathy	6.56e-05	0.000215	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CXCR3—dilated cardiomyopathy	6.56e-05	0.000215	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—AGT—dilated cardiomyopathy	6.55e-05	0.000215	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	6.54e-05	0.000215	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—AGT—dilated cardiomyopathy	6.46e-05	0.000212	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—ADRB1—dilated cardiomyopathy	6.44e-05	0.000211	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—ADRB1—dilated cardiomyopathy	6.35e-05	0.000209	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.34e-05	0.000208	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.21e-05	0.000204	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	6.18e-05	0.000203	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.11e-05	0.000201	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PSEN2—dilated cardiomyopathy	6.08e-05	0.0002	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	6.08e-05	0.0002	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—ADRB2—dilated cardiomyopathy	6.01e-05	0.000198	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PSEN2—dilated cardiomyopathy	5.98e-05	0.000197	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PSEN2—dilated cardiomyopathy	5.97e-05	0.000196	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—ADRB2—dilated cardiomyopathy	5.89e-05	0.000193	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—AGTR1—dilated cardiomyopathy	5.83e-05	0.000192	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—ADRB2—dilated cardiomyopathy	5.79e-05	0.00019	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—RAC1—dilated cardiomyopathy	5.7e-05	0.000187	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	5.67e-05	0.000186	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	5.61e-05	0.000184	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	5.59e-05	0.000184	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	5.59e-05	0.000184	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	5.53e-05	0.000182	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—ADRB2—dilated cardiomyopathy	5.53e-05	0.000182	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	5.52e-05	0.000182	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—AGTR1—dilated cardiomyopathy	5.5e-05	0.000181	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—AGT—dilated cardiomyopathy	5.44e-05	0.000179	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—AGTR1—dilated cardiomyopathy	5.42e-05	0.000178	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CXCL2—dilated cardiomyopathy	5.4e-05	0.000177	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—AGTR2—dilated cardiomyopathy	5.4e-05	0.000177	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—GPX1—dilated cardiomyopathy	5.37e-05	0.000177	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—AGT—dilated cardiomyopathy	5.36e-05	0.000176	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—AGT—dilated cardiomyopathy	5.35e-05	0.000176	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—AGTR2—dilated cardiomyopathy	5.31e-05	0.000174	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CXCL2—dilated cardiomyopathy	5.31e-05	0.000174	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CXCL2—dilated cardiomyopathy	5.3e-05	0.000174	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—AGTR2—dilated cardiomyopathy	5.3e-05	0.000174	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	5.27e-05	0.000173	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—RAF1—dilated cardiomyopathy	5.24e-05	0.000172	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—CD36—dilated cardiomyopathy	5.23e-05	0.000172	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—ADRB2—dilated cardiomyopathy	5.22e-05	0.000171	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—RAC1—dilated cardiomyopathy	5.17e-05	0.00017	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	5.17e-05	0.00017	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.17e-05	0.00017	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—ADRB2—dilated cardiomyopathy	5.15e-05	0.000169	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—RAF1—dilated cardiomyopathy	5.13e-05	0.000169	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—RAC1—dilated cardiomyopathy	5.09e-05	0.000167	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—RAC1—dilated cardiomyopathy	5.08e-05	0.000167	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.06e-05	0.000166	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—RAF1—dilated cardiomyopathy	5.05e-05	0.000166	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	5.04e-05	0.000166	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CXCR3—dilated cardiomyopathy	5.02e-05	0.000165	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.98e-05	0.000164	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	4.97e-05	0.000163	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—AGT—dilated cardiomyopathy	4.94e-05	0.000162	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CXCR3—dilated cardiomyopathy	4.94e-05	0.000162	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CXCR3—dilated cardiomyopathy	4.93e-05	0.000162	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—AGT—dilated cardiomyopathy	4.86e-05	0.00016	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—ADRB1—dilated cardiomyopathy	4.86e-05	0.00016	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—AGT—dilated cardiomyopathy	4.85e-05	0.000159	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—RAF1—dilated cardiomyopathy	4.82e-05	0.000158	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—ADRB1—dilated cardiomyopathy	4.78e-05	0.000157	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—ADRB1—dilated cardiomyopathy	4.77e-05	0.000157	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.75e-05	0.000156	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—AGT—dilated cardiomyopathy	4.71e-05	0.000155	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—RAC1—dilated cardiomyopathy	4.67e-05	0.000153	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—RAC1—dilated cardiomyopathy	4.57e-05	0.00015	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—RAF1—dilated cardiomyopathy	4.54e-05	0.000149	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	4.54e-05	0.000149	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—GPX1—dilated cardiomyopathy	4.52e-05	0.000149	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—RAC1—dilated cardiomyopathy	4.5e-05	0.000148	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—RAF1—dilated cardiomyopathy	4.48e-05	0.000147	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.48e-05	0.000147	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—AGT—dilated cardiomyopathy	4.46e-05	0.000147	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.42e-05	0.000145	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	4.42e-05	0.000145	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—CD36—dilated cardiomyopathy	4.4e-05	0.000145	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—AGT—dilated cardiomyopathy	4.37e-05	0.000143	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	4.3e-05	0.000141	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—AGT—dilated cardiomyopathy	4.3e-05	0.000141	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—RAC1—dilated cardiomyopathy	4.29e-05	0.000141	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.15e-05	0.000136	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—AGT—dilated cardiomyopathy	4.1e-05	0.000135	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.08e-05	0.000134	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.07e-05	0.000134	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—RAC1—dilated cardiomyopathy	4.05e-05	0.000133	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—RAC1—dilated cardiomyopathy	3.99e-05	0.000131	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—AGT—dilated cardiomyopathy	3.96e-05	0.00013	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.94e-05	0.000129	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	3.88e-05	0.000127	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.87e-05	0.000127	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—AGT—dilated cardiomyopathy	3.87e-05	0.000127	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.87e-05	0.000127	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—AGT—dilated cardiomyopathy	3.82e-05	0.000125	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.59e-05	0.000118	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.52e-05	0.000116	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.46e-05	0.000114	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—RAF1—dilated cardiomyopathy	3.43e-05	0.000113	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.38e-05	0.000111	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—RAF1—dilated cardiomyopathy	3.38e-05	0.000111	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—RAF1—dilated cardiomyopathy	3.37e-05	0.000111	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.33e-05	0.000109	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.32e-05	0.000109	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.3e-05	0.000109	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—GPX1—dilated cardiomyopathy	3.27e-05	0.000107	CbGpPWpGaD
Haloperidol—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	3.2e-05	0.000105	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—CD36—dilated cardiomyopathy	3.18e-05	0.000105	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.12e-05	0.000102	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—RAF1—dilated cardiomyopathy	3.09e-05	0.000102	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—GPX1—dilated cardiomyopathy	3.09e-05	0.000101	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.07e-05	0.000101	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—RAC1—dilated cardiomyopathy	3.06e-05	0.0001	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—RAF1—dilated cardiomyopathy	3.03e-05	9.96e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—RAC1—dilated cardiomyopathy	3.01e-05	9.88e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—CD36—dilated cardiomyopathy	3.01e-05	9.88e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—RAC1—dilated cardiomyopathy	3e-05	9.86e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—RAF1—dilated cardiomyopathy	2.98e-05	9.8e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—AGT—dilated cardiomyopathy	2.92e-05	9.6e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—AGT—dilated cardiomyopathy	2.87e-05	9.44e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—AGT—dilated cardiomyopathy	2.87e-05	9.42e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—AGT—dilated cardiomyopathy	2.87e-05	9.41e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—RAF1—dilated cardiomyopathy	2.85e-05	9.35e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—AGT—dilated cardiomyopathy	2.71e-05	8.89e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—RAF1—dilated cardiomyopathy	2.68e-05	8.82e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—RAF1—dilated cardiomyopathy	2.65e-05	8.7e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—GPX1—dilated cardiomyopathy	2.53e-05	8.3e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	2.47e-05	8.1e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—CD36—dilated cardiomyopathy	2.46e-05	8.08e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—CD36—dilated cardiomyopathy	2.4e-05	7.89e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.35e-05	7.73e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	2.32e-05	7.63e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.32e-05	7.61e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.31e-05	7.59e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—GPX1—dilated cardiomyopathy	2.3e-05	7.57e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	2.26e-05	7.43e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CD36—dilated cardiomyopathy	2.24e-05	7.37e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—AGT—dilated cardiomyopathy	2.22e-05	7.28e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—AGT—dilated cardiomyopathy	2.16e-05	7.1e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—EGFR—dilated cardiomyopathy	2.12e-05	6.97e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—EGFR—dilated cardiomyopathy	2.08e-05	6.83e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—EGFR—dilated cardiomyopathy	2.04e-05	6.72e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	2.04e-05	6.69e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—RAF1—dilated cardiomyopathy	2.03e-05	6.66e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—AGT—dilated cardiomyopathy	2.02e-05	6.64e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—RAF1—dilated cardiomyopathy	1.99e-05	6.55e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—RAF1—dilated cardiomyopathy	1.99e-05	6.54e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—GPX1—dilated cardiomyopathy	1.97e-05	6.47e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—EGFR—dilated cardiomyopathy	1.95e-05	6.41e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CD36—dilated cardiomyopathy	1.92e-05	6.3e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.84e-05	6.05e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—EGFR—dilated cardiomyopathy	1.82e-05	5.97e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—AGT—dilated cardiomyopathy	1.73e-05	5.67e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	1.52e-05	4.99e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	1.48e-05	4.86e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—EGFR—dilated cardiomyopathy	1.39e-05	4.57e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—EGFR—dilated cardiomyopathy	1.37e-05	4.49e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.36e-05	4.48e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	1.33e-05	4.38e-05	CbGpPWpGaD
